Indefinite Delivery Contract 75N93022D00017
Award Date
1/14/22
Last Date to Order
1/13/32
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
PPD Development LP
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Cost Plus Fixed Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to PPD Development LP with a potential value of $545,452,906 to provide comprehensive and rapid response capabilities for research programs through September 2028. Task orders issued against the contract include over $132 million for clinical trial management support services relating to COVID-19, as well as orders valued at $2.33 million, $2 million, and $82.5...
The contract is an Indefinite Delivery Contract (IDC) awarded by the Defense Health Agency (DHA), a component of the Department of Defense (DoD), to PPD Development LP, a global contract research organization (CRO). The $2,500 task order is for military medical research and development services and is part of a larger $545 million IDC held by PPD Development LP with the National Institute of Allergy and Infectious Diseases (NIAID). PPD Development LP has been awarded several significant IDCs...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), awarded a $346.6 million multiple-award Indefinite Delivery Contract (IDC) called the Early Phase Clinical Trial Units (EPCTU) program. This IDC supports Phase 0 through Phase III clinical trials of investigational products against infectious diseases, including small molecules, monoclonal antibodies, vaccines, and other medical countermeasures. The prime...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded an indefinite-delivery/indefinite-quantity (IDIQ) contract to Duke University's Office of Research Administration Division to support Phase 0 through Phase II clinical trials of investigational products against infectious diseases. The IDIQ contract, valued at up to $346,610,277, has a performance period from January 14, 2022 to January 13, 2032. Under this IDIQ, Duke...
The federal contract IDV award is for the National Institute of Allergy and Infectious Diseases' (NIAID) Early Phase Clinical Trial Units (EPCTU) program. The $346.6 million, multiple-award IDIQ contract was awarded to Icon Government And Public Health Solutions, Inc., a foreign-owned, for-profit organization that specializes in providing comprehensive clinical research services to federal agencies, particularly in the areas of medical countermeasure development and public health emergency...
This $49.9 million Indefinite Delivery Contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific. The contract is for research and development related to clinical studies under NIDA's Blueprint MedTech program, which focuses on medical technology development for nervous system disorders. Under this IDC, PPD will provide a range of services including developing...
This single-award IDV was issued by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to provide centralized clinical laboratory services in support of clinical research trials. With a potential value of $5,000,000 and a period of performance through May 2026, the awardee PPD Development LP will deliver services including specimen handling, testing, data management, and clinical trial support. The originating...
The National Institute of Allergy and Infectious Diseases awarded an indefinite delivery contract to FHI Clinical Inc. to provide comprehensive and rapid response research programs. The contract has a potential value of $545,452,906 over a seven-year ordering period through August 2028. Two task orders have been issued against it to date, one for $332,178 and another for $2,000. Under the contract, FHI Clinical Inc. will support the NIAID's mission to conduct biomedical research on infectious,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, awarded a $146.3 million Indefinite Delivery Contract (IDC) to Institute For Clinical Pharmacodynamics, Inc., a for-profit organization, to provide pre-clinical models of infectious diseases under Task Area C. The period of performance is from July 15, 2024 to July 14, 2031. The contract is a follow-on to a previous Preclinical Models of Infectious Diseases...
This Indefinite Delivery Contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Dynport Vaccine Company LLC, a subsidiary of General Dynamics. The contract, valued at a ceiling of $346,610,277, is for Early Phase Clinical Trial Units (EPCTU) services to support Phase 0 through Phase II clinical trials of investigational products targeting infectious diseases. The contract has a period of performance through...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Delivery Order 75N93022D00017-75N93022F00001 | PPD Development LP | $1.9m | 1/14/22 | 1/13/26 | 1/12/25 | |
Delivery Order 75N93022D00017-75N93023F00001 | PPD Development LP | $2.8m | 6/29/23 | 10/31/25 | 8/11/25 |